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The reciprocal communication between cancer cells and their microenviron-
ment is critical in cancer progression. Although involvement of cancer-
associated fibroblasts (CAF) in cancer progression is long established, the
molecular mechanisms leading to differentiation of CAFs from normal
fibroblasts are poorly understood. Here, we report that kallikrein-related
peptidase-4 (KLK4) promotes CAF differentiation. KLK4 is highly
expressed in prostate epithelial cells of premalignant (prostatic intraepithe-
lial neoplasia) and malignant lesions compared to normal prostate epithe-
lia, especially at the peristromal interface. KLK4 induced CAF-like
features in the prostate-derived WPMY1 normal stromal cell line, including
increased expression of alpha-smooth muscle actin, ESR1 and SFRP1.
KLK4 activated protease-activated receptor-1 in WPMY1 cells increasing
expression of several factors (FGF1, TAGLN, LOX, IL8, VEGFA)
involved in prostate cancer progression. In addition, KLK4 induced
WPMY1 cell proliferation and secretome changes, which in turn stimulated
HUVEC cell proliferation that could be blocked by a VEGFA antibody.
Importantly, the genes dysregulated by KLK4 treatment of WPMY1 cells
were also differentially expressed between patient-derived CAFs compared
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to matched nonmalignant fibroblasts and were further increased by KLK4
treatment. Taken together, we propose that epithelial-derived KLK4 pro-
motes tumour progression by actively promoting CAF differentiation in
the prostate stromal microenvironment.
1. Introduction
Malignant tumours are formed from cancer cells in a
complex tumour microenvironment (TME) producing
a large variety of bioactive factors [growth factors,
cytokines and extracellular matrix (ECM) proteins]
that regulate tumour growth, angiogenesis and metas-
tasis (Gkretsi et al., 2015; Mbeunkui and Johann,
2009; Shiao et al., 2016). In solid tumours, stromal
cells such as adipocytes, fibroblasts and myofibroblasts
are the most predominant nonimmune cell populations
composing the TME (Doldi et al., 2015; Gandellini
et al., 2015). In particular, the appearance of cancer-
associated-fibroblasts (CAFs) is a key step in initiation
and progression of tumorigenesis as well as for the
development of drug-resistant capacities in cancer cells
(Gandellini et al., 2015; Gascard and Tlsty, 2016;
Shiao et al., 2016). The cellular origin of CAFs is
greatly dependent on the tumour type. In the case of
prostate cancer (PCa), establishment of reactive stroma
is already observable in the premalignant lesion, pro-
static intraepithelial neoplasia (PIN), including
through differentiation of normal fibroblasts and
myofibroblasts surrounding the lesions (Augsten, 2014;
Tuxhorn et al., 2002). Differentiation of normal cells
into CAFs is a complex and dynamic process, which is
often summarized as a three-step process (Madar
et al., 2013). Firstly, premalignant cells recruit adja-
cent or distant normal cells through paracrine and
endocrine signals; secondly, signals emitted by prema-
lignant cells induce a particular phenotype in normal
cells; and finally, persistence signals, produced by pre-
malignant/malignant cells, enable the maintenance,
expansion and evolution of CAF populations with
cancer progression. In return, CAF populations pro-
duce paracrine signals that influence cancer progres-
sion (Augsten, 2014; Mbeunkui and Johann, 2009).
Populations of CAFs are heterogeneous between
tumours as well as between different compartments
and developmental stages of each tumour (Augsten,
2014; De Wever et al., 2014; Gascard and Tlsty, 2016;
Ishii et al., 2011). For instance, it is recognized that
CAFs associated with primary tumours are different
from those found at metastatic sites (De Wever et al.,
2014). Although several markers are generally
recognized as expressed in CAFs, such as a-smooth
muscle actin (SMA) and fibroblast activation protein
a, the heterogeneity of CAFs makes it difficult to
determine a specific set of molecular markers to char-
acterize the CAF phenotype. This variability of CAF
populations reflects the heterogeneity of signals and
associated molecular mechanisms controlling the dif-
ferentiation of normal cells into CAFs. Several sig-
nalling pathways are known to be involved in CAF
differentiation, including transforming growth factor-b
(TGF-b) and interleukin-6 (IL6). These pathways can
induce a partial CAF phenotype in normal prostate
fibroblasts (NPFs) in vitro, but an ensemble of signals
rather than a single factor are necessary to mimic dif-
ferentiation in vivo (Bruzzese et al., 2014; Doldi et al.,
2015; Franco et al., 2011; Webber et al., 2015). In
addition, modification of ECM composition and
matrix stiffness during tumour formation induces
mechanical signals which, together with soluble fac-
tors, stimulate stromal cell activation (De Veirman
et al., 2014). The identification of other signalling fac-
tors required for differentiation of normal cells into
CAFs is crucial to understand the processes associated
with establishment of the TME.
Proteolytic networks play a central role in establish-
ment of the TME by remodelling the physical environ-
ment of cancer cells and regulating their interactions
with nonmalignant cells (Mason and Joyce, 2011). The
kallikrein-related peptidases (KLKs) comprise a family
of 15 secreted serine proteases involved in a multitude
of physiological processes and which are deregulated
during cancer progression (Kryza et al., 2016;
Lawrence et al., 2010). In PCa, several KLKs are
deregulated, notably KLK3/prostate-specific antigen,
which has been used in PCa diagnosis and tumour
recurrence monitoring for over 25 years. In addition,
KLK4 is also overexpressed in PCa and involved in
processes critical for establishment of the TME and
cancer progression (Dong et al., 2005; Karakosta
et al., 2016; Mukai et al., 2015; Seiz et al., 2010).
KLK4 exerts autocrine effects on cancer cells and
paracrine effects on surrounding normal cells, in turn
regulating key signalling pathways (Gao et al., 2007;
Mukai et al., 2015; Ramsay et al., 2008a; Wang et al.,
2010). Notably, KLK4 activates secreted molecules
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such as hepatocyte growth factor/scatter factor (HGF-
SF) (Mukai et al., 2008, 2015), insulin-like growth
factor (IGF) (Matsumura et al., 2005) and TGF-b
(Shahinian et al., 2014). KLK4 participates in ECM
remodelling (Matsumura et al., 2005; Shahinian et al.,
2014; Zhu et al., 2014) and acts directly on target cells
through proteolysis of membrane-tethered proteins,
such as the ephrin B4 receptor (Lisle et al., 2015) and
protease-activated receptors (PARs) (Gratio et al.,
2010; Ramsay et al., 2008a,b; Wang et al., 2010).
Interestingly, elevated expression and activation of
PARs is associated with progression of several cancers
including PCa (Han et al., 2011; Ramachandran et al.,
2012).
In this study, we identified that, in addition to being
overexpressed in PCa lesions, KLK4 is also elevated in
hyperplastic prostate epithelial cells and PIN lesions,
where it can interact with adjacent stromal cells.
Through activation of PAR1 expressed in the normal
prostate stromal cell line WPMY1, KLK4 regulates
the expression of several factors involved in the estab-
lishment of the CAF phenotype, stimulates cell prolif-
eration and modulates the secretome of stromal cells,
increasing its proangiogenic capacity. We confirmed
that these factors are similarly regulated in CAFs
compared to matched NPFs and that KLK4 can also
regulate this same set of genes in patient-derived NPFs
and CAFs. In view of these results, we propose that
the secretion of KLK4 by prostate preneoplastic cells
is involved in the induction of the CAF phenotype in
prostate normal stromal cells, a key step for the initia-
tion of PCa.
2. Materials and methods
2.1. Reagents
All reagents and materials were purchased in Aus-
tralia. PAR-1 activating peptide (AP1; TFLLR-NH2)
and PAR-2 activating peptide (AP2; SLIGKV-NH2)
were purchased from Auspep (Parkville, Vic., Aus-
tralia). Fura-2 acetoxymethyl ester was obtained from
Thermo Fisher (Newstead, Qld, Australia). Antibodies
were purchased from the following vendors: anticytok-
eratin (high molecular weight; 4bE12; Dako, Camp-
bellfield, Vic., Australia), anti-TAGLN antibody
(HPA019467; Sigma-Aldrich, Castle Hill, NSW, Aus-
tralia), anti-b-actin antibody (ab8226; Abcam,
Melbourne, Vic., Australia), anti-aSMA (SP171;
Sigma-Aldrich), antivimentin (antiVEM, PA5-27231;
Thermo Fisher), anti-VEGF (500-P10-50; Lonza,
Mount Waverley, Vic., Australia), rabbit IgG isotype
control and secondary antibodies (Thermo Fisher).
DAPI counterstaining compound and CyQuant cell
proliferation assay were purchased from Thermo
Fisher. The protease inhibitor cocktail and other
chemical reagents were purchased from Sigma-Aldrich,
except when specified. The Envision peroxidase system
and Fast Red Substrate System were purchased from
Dako. All cell culture media and reagents were pur-
chased from Thermo Fisher, Australia, except for fetal
bovine serum (FBS), which was from Sigma-Aldrich.
2.2. Tissue/sample preparation and
immunohistochemistry (IHC)
Human prostate tissue samples were obtained as forma-
lin-fixed and paraffin-embedded blocks from the archives
of the Department of Pathology Royal Brisbane and
Women’s Hospital, Queensland, Australia. Ethics
approval was obtained from the respective Institutional
Ethics Committees (QUT1000001171), and informed
consent was obtained from all patients. The 32 samples
examined by immunohistochemical staining included
one normal prostate, 12 benign prostatic hyperplasia
(BPH), 19 PCas with different Gleason grades. Five-
micrometre-thick sections were cut and mounted on
3-aminopropyltriethoxysilane (Sigma-Aldrich)-coated
slides. These sections were then subjected to IHC as
described previously (Dong et al., 2005; Veveris-Lowe
et al., 2005) using an affinity-purified anti-KLK4 pep-
tide antibody raised against the N terminus (IIN-
GEDCSPHSQ). For better visualization of the basal
cells in adjacent normal prostate glands, the Fast Red
Substrate System was utilized for the detection of the
antibody against high molecular weight cytokeratin
34bE12 as per the company’s instructions. Negative
controls were performed with mouse or rabbit IgG
instead of primary antibodies. Negative controls also
included a preincubated anti-KLK4 antibody with the
recombinant KLK4 protein (KLK4/anti-KLK4, 1/2,
w/w, 2 h at room temperature). All sections were
examined by a pathologist (H.S.) to confirm
histopathological features for comparison of the IHC
staining intensity (Fig. 1B, Table S2). The staining
intensity of sections was scored according to a scale
from 0 to 3 (0, no staining; 1, weak positive; 2, mod-
erately positive; 3, strongly positive) by three indepen-
dent observers (Loan Bui, Ying Dong and Hemamali
Samaratunga). At least five glands or regions in each
defined category were examined. One-way ANOVA
and Tukey’s multiple comparisons test were used to
assess the staining intensity difference among the
abovementioned pathological and clinical parame-
ters, with P ≤ 0.05 considered to be statistically signif-
icant.
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2.3. Cell lines and primary cells
All cell lines were obtained from ATCC (Manassas,
VA, USA): normal prostate stromal cell line
(WPMY1), transformed prostate epithelial cell lines
(RWPE1 and RWPE2), androgen receptor-positive,
androgen-responsive PCa cell lines (LNCaP, C42B and
22RV1), androgen receptor-negative, androgen-
insensitive PCa cell lines (DU145 and PC-3), human
umbilical vein endothelial cells (HUV-EC-C) and
benign prostate hyperplastic epithelial cells (BPH1).
Matched primary NPFs and CAFs were isolated from
nonmalignant and tumour regions of patient radical
prostatectomy specimens as previously described
(Clark et al., 2013; Lawrence et al., 2013). These sam-
ples were obtained with human ethics approval from
Monash University (2004/145), Cabrini Hospital (03-
14-04-08), under the auspices of the Australian Pros-
tate Cancer BioResource (APCB) and Epworth Hospi-
tal (53611). All primary fibroblasts were cultivated in
RPMI 1640 containing 5% FBS and 10 ngmL1 basic
fibroblast growth factor (FGF; Merck-Millipore,
Bayswater, Vic., Australia) and used between passage
3 and passage 6 after isolation. All cells were grown in
a 5% CO2-humidified atmosphere at 37 °C following
the supplier’s recommended culture conditions, except
when specified.
2.4. Recombinant wild-type KLK4 and mutant
KLK4
Full-length wild-type recombinant KLK4 was generated
as previously described (Ramsay et al., 2008a). In addi-
tion, the coding sequence of wild-type KLK4 was modi-
fied to produce a double-mutant KLK4 (mKLK4)
corresponding to wild-type KLK4 with the amino acids
serine207 and aspartate116, in the catalytic triad mutated
to an alanine207 and asparagine116, respectively, in order
to inhibit KLK4 proteolytic activity.
2.5. Measurement of intracellular Ca2+ flux
Cells grown to 80% confluence were washed with
phosphate-buffered saline (PBS), detached nonenzy-
matically using Versene (Thermo Fisher), resuspended
(4 9 106 cellsmL1) and loaded with the fluorescence
indicator fura-2 acetoxymethyl ester (1.0 lM; Thermo
Fisher) for 1 h at 37 °C in buffer containing 25 mM
HEPES pH 7.4, 121 mM NaCl, 5.4 mM KCl, 0.8 mM
MgCl2, 1.8 mM CaCl2, 5.5 mM glucose, 2.5 mM probe-
necid and 0.01% (v/v) pluronic acid. Then, cells were
washed with PBS and resuspended at 2 9 106
cellsmL1 in the same buffer, lacking fura-2 and
pluronic acid for fluorescence measurements. The ratio
of fluorescence at 510 nM after excitation at 340 and
380 nM was monitored using a Polarstar Optima fluo-
rescent plate reader (BMG Labtech Pty Ltd, Morning-
ton, Qld, Australia). Single agonist treatments were
performed at 37 °C with KLK4 and mKLK4
(300 nM), AP1 and AP2 (100 lM). Desensitization
experiments were performed following the same experi-
mental procedure, and cells were treated successively
with two agonists (t1 = 30 s and t2 = 480 s). For cal-
cium flux experiments in the presence of PAR1 inhibi-
tor (SHC 79797), cells were pretreated with SHC
79797 (0.3 and 0.7 lM) or vehicle (DMSO) and assays
were performed following the same experimental pro-
cedure than previously but in the presence of SHC
79797 (same doses than pretreatment). Displayed data
are representative of experiments performed in dupli-
cate and repeated on three independent occasions
[mean  standard deviation (SD)].
2.6. RNA isolation, reverse transcription and
qPCR for gene expression analysis
For the analysis of basal gene expression level in pros-
tate-derived cell lines, cells were grown until 80% con-
fluent in their respective media and RNA was extracted
as described below. For analysis of basal gene expres-
sion in NPFs and CAFs, cells were seeded in six-well
plates (50 000 cells per well) in RPMI 1640 containing
5% FBS and 10 ngmL1 FGF. After 48 h, cells were
starved in serum-free medium overnight and RNA was
extracted as described below. To analyse the impact of
PAR activation on gene expression in prostate stromal
cells (WPMY1, NPF and CAF), cells were seeded in six-
well plates (50 000 cells per well) in their respective
medium and grown for 48 h. Then, cells were starved
overnight in serum-free medium before being treated
with mKLK4 (20 nM), KLK4 (20 nM), AP1 (100 lM) or
AP2 (100 lM) during the specified time. In some experi-
ments, PAR-1 inhibitor SHC79797 dihydrochloride (0.3
and 0.7 lM; In Vitro Technologies Pty Ltd, Noble Park,
Vic., Australia,) was added as an antagonist. For experi-
ments with cells transfected with siRNA, the same pro-
tocol was used but siRNA transfection was performed
24 h after seeding (see below).
RNA extraction from cells was performed using the
ISOLATE II RNA Kit (Bioline, Eveleigh, NSW, Aus-
tralia) and reverse-transcribed (RT) using random hex-
amer primers and Superscript III (Thermo Fisher).
Quantitative PCR (qPCR) was carried out using
SYBR Green master mix (Thermo Fisher) and specific
primers (Sigma-Aldrich, Table S1) on a ViiATM 7
Real-Time PCR System (Thermo Fisher). mRNA
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expression was determined using the delta-delta CT
method and using 7SL or RPL32 gene expression as
housekeeping genes. Data presented correspond to
mean  standard error (SE) from three independent
experiments.
2.7. siRNA transfection
In order to knockdown the expression of PAR1 or
FGF1, WPMY1 cells were transfected with siRNA
targeting PAR-1 (SMART pool ON-TARGET plus
F2R; Millennium Science, Mulgrave, Qld, Australia),
FGF1 (SMART pool ON-TARGET plus FGF1;
Millennium Science) or control-siRNA (Control pool
ON-TARGET plus cyclophilin B; Millennium Science)
following the manufacturer’s instructions. Briefly,
WPMY1 cells were seeded in six-well plates
(50 000 cells per well) in RPMI 1640 containing 5%
FBS. After 24 h, medium was replaced by RPMI 1640
containing 5% FBS, 25 nM of siRNA and 5 lL of
DharmaFECT 1 transfection reagent (Millennium
Science). After 24 h, medium was replaced with serum-
free RPMI 1640 for PAR agonist treatment or with
RPMI 1640 containing 5% FBS for calcium flux
assays. Knockdowns were confirmed at the mRNA
level by RTqPCR and at the protein level by calcium
flux assay for PAR1 and enzyme-linked immunosor-
bent assay (ELISA) for FGF1.
2.8. ELISAs for FGF1, IL8 and VEGF
The concentration of FGF1 in cellular lysates was
measured using a specific FGF1 ELISA (DFA00B;
Thermo Fisher). IL8 and VEGF levels in WPMY1-
conditioned medium (CM) were measured using
specific IL8 and VEGF ELISAs (900-M18, 900-M10;
Lonza Australia Pty Ltd, Mt Waverly, Vic., Aus-
tralia). Briefly, the CM was harvested after treatment,
centrifuged to eliminate cellular debris and stored at
80 °C. Cellular proteins were extracted on ice using
ELISA lysis buffer (100 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100,
0.5% sodium deoxycholate and protease inhibitor
cocktail), and protein concentration was determined
by the bicinchoninic acid assay (BCA) (Sigma-
Aldrich). FGF1 ELISA was performed on 30 lg of
lysate and ELISAs for IL8 and VEGF were per-
formed on 100 lL of CM using protocols recom-
mended by the manufacturer. Results are expressed
in picograms (pg) FGF1 protein/30 lg total protein
or in pg IL8 or VEGFmL1 of CM. The results pre-
sented correspond to mean  SD of three biological
replicates.
2.9. Western blot
Whole-cell proteins were extracted on ice using RIPA
lysis buffer (150 mM sodium chloride, 1.0% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
sodium orthovanadate, 1 mM NaF, 50 mM Tris, pH
8.0, containing protease inhibitor cocktail) and an
equal quantity of protein (BCA assay) was separated
by SDS/PAGE NuPAGE 4–12% using MOPS buffer
(50 mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM
EDTA, pH 7.7) and transferred onto PVDF mem-
branes by liquid transfer. After blocking, PVDF mem-
branes were incubated with respective primary
antibodies diluted in TBS-T (TBS + 0.1% Tween-20)
containing 5% BSA overnight at 4 °C, followed by
incubation with species-appropriate AlexaFluor 680 or
IRdye 800-conjugated secondary antibodies for
45 min. Membranes were scanned on an Odyssey
infrared imaging system (LiCor, Mulgrave, Vic., Aus-
tralia). Consistent protein loading and transfer was
determined by reanalysing membranes with either an
antiactin or antiVEM antibody, and densitometry
analysis was carried out using IMAGEJ software (https://
imagej.nih.gov/ij/).
2.10. Immunofluorescent staining
WPMY1 cells were seeded on poly-lysine-coated cover-
slips and cultured for 48 h in RPMI 1640 containing
5% FBS. Then, cells were starved overnight and trea-
ted with mKLK4, KLK4 (20 nM) or AP1 (100 lM) for
48 h. After treatment, cells were fixed and incubated
overnight at 4 °C with an anti-TAGLN or anti-aSMA
antibody, followed by incubation with species-
appropriate secondary antibody coupled with Alexa
Fluor 488 conjugate. Cell nuclei were stained with
DAPI before imaging with an Olympus FV1200 laser
scanning confocal microscope. For aSMA staining,
WPMY1 cells were seeded in 96-well plates (5000 cells
per well) in RPMI 1640 + 5% FBS. After 24 h, cells
were treated with mKLK4, KLK4 (20 nM) or AP1
(100 lM) over 6 days (treatment renewed every 48 h).
Cells were washed and fixed, incubated as above with
an anti-aSMA antibody and then a goat anti-mouse
IgG (H+L) secondary antibody coupled with Alexa
Fluor 488 conjugate and nuclei were stained with
DAPI. Imaging was performed with an epifluorescent
microscope (IX73 Olympus inverted microscope
system) and quantitative measurement was taken
using the Incucyte live cell imaging system (Essen
BioScience, Ann Arbor, MI, USA). Results presented
correspond to mean of fluorescence units  SD
obtained in three independent experiments.
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2.11. Proliferation of WPMY1 cells
In order to determine the impact of KLK4 and AP1
treatment on stromal cell proliferation, WPMY1 cells
were seeded in 96-well plates (5000 cells per well) in
RPMI 1640 + 5% FBS. After 24 h, cells were treated
with mKLK4, KLK4 (20 nM) or AP1 (100 lM) for
6 days (treatment renewed every 48 h). After 24, 48, 72
and 96 h of treatment, cells were washed and fixed and
nuclei were stained using DAPI. Cells were imaged
using the Cytell Cell Imaging System (VWR Interna-
tional Pty Ltd, Tingalpa, Qld, Australia) and the num-
ber of cells per well was determined using the
CELLPROFILER software (www.cellprofiler.org) based on
DAPI staining. Results presented correspond to mean
of number of cells per well  SD calculated on four bio-
logical replicates containing three technical replicates.
2.12. Analysis of WPMY1 secretome by cytokine
protein array
WPMY1 cells were treated as previously with mKLK4
or KLK4 (20 nM) for 48 h. CM was collected and the
WPMY1 cell secretome was analysed using the Pro-
teome Profiler Human XL Cytokine Array Kit (Thermo
Fisher) according to the manufacturer’s instructions.
Results are expressed as mean of relative intensity (%)
of duplicate spots, compared to mean intensity of six
positive control spots of each array.
2.13. Impact of WPMY1 secretome on
proliferation of HUV-EC-C
WPMY1 cells were cultured as described above and
treated with mKLK4, KLK4 (20 nM) or AP1
(100 lM). After 48 h, CM was recovered and spun at
2000 G for 10 min at 4 °C to eliminate cell debris.
For live imaging assay, HUV-EC-C cells were plated
in 96-well plates (2000 cells) in recommended growth
medium. After 24 h, cells were washed with basal med-
ium before being treated with WPMY1 CM. Conflu-
ence was followed using Incucyte for 48 h. Results are
presented as mean of relative confluence (%) com-
pared to confluence of HUV-EC-C cells treated for
24 h with CM from WPMY1 cells treated with
mKLK4. Results were calculated for three independent
biological replicates. For Cyquant DNA assay, HUV-
EC-C cells were plated as described above. After 24 h,
cells were washed with basal medium before being
treated with WPMY1 CM or normal endothelial cell
growth medium (EGM) containing isotype IgG control
antibody or anti-VEGF-neutralizing antibody. The
CyQuant proliferation assay was performed after 48 h
of treatment. Results are presented as mean of relative
fluorescence (%) compared to confluence of HUV-EC-C
cells treated 48 h with CM of WPMY1 treated with
mKLK4 containing isotype IgG control. Results were
calculated on three independent biological replicates.
2.14. Statistical analysis
Statistical analysis was performed with GraphPad
Prism, GraphPad Software, Inc., La Jolla, CA, USA.
Unless otherwise stated, statistical analysis was per-
formed using the Kruskal and Wallis test with
*P < 0.05, **P < 0.01, ***P < 0.001.
3. Results
3.1. KLK4 is produced in premalignant and
malignant prostatic lesions
KLK4 protein expression in prostate was examined
using IHC, with representative images shown in
Fig. 1A. Normal glands (normal, Fig. 1Aa) and under-
lying basal cells (closed arrows, Fig. 1Aa) expressed
Fig. 1. KLK4 expression in the progression of prostate cancer and in foci of atypical suspicious prostate glands. (A) IHC staining of KLK4 in
prostate tissues. (a) PIN lesion and adjacent normal glands (Normal, arrows). (b) Low-grade PIN (LGPIN) with positive staining of basal cells
(closed arrows) and no staining in stromal cells (open arrow head). (c) High-grade PIN (HGPIN) lesions with positive staining in both the
nucleus (open arrows) and cytoplasm (arrows) of the secretory cells. (d–f) Strong intensity of KLK4 staining in prostate cancer lesions (Ca or
arrows) compared to weak staining of an adjacent normal glands and stroma (Normal and open arrow heads). (g) Anti-KLK4 antibody
absorbance showing no staining, as a negative control. Scale bars are as indicated. (B) Comparison of KLK4 staining intensity in prostate
tissues with different Gleason grades. Average staining intensity (●) and SD are shown. Number of region analysed per lesion type is
indicated after each lesion name. One-way ANOVA test, *P < 0.05 compared to normal and #P < 0.05 compared to benign prostatic
hyperplasia (BPH). Details can be found in Tables S2 and S3. 1Note that the ‘normal’ prostate sample comprises scores for the single
normal prostate tissue specimen and 15 tumour-adjacent normal prostate tissue regions. (C) (a–d) Low and high magnification of cells in
adjacent normal gland showing strong KLK4 staining (box), with the high KLK4 foci appearing to have no basal cells (arrow). (e–g) Low and
high magnifications of double staining of high molecular weight cytokeratin 34bE12 and KLK4 in normal prostate gland, showing the KLK4
expressing foci (brown) with disappearing basal cells (arrow) compared to the basal cell layer expressing 34bE12 (pink) in the surrounding
area. Scale bars are as indicated. PIN, prostatic intraneoplasia; Ca, cancer.
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low levels of KLK4. In prostatic intraepithelial neo-
plasia (PIN) lesions, KLK4 staining was strong and
predominantly localized to the cytoplasm of the secre-
tory cells of prostate glands (Fig. 1Aa–c), and the basal
cells of low- and high-grade PIN lesions (LGPIN,
HGPIN, closed arrows, Fig. 1Ab–c). KLK4
immunoreactivity was present in the cytoplasm of
Gleason grade 3 + 3, 3 + 4, 4 + 5 cancers (Fig. 1Ad–f).
Although the major site of KLK4 immunostaining was
the cytoplasm, nuclear staining was occasionally
gfed
a b c
A
a b e
B
C
c d f g
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detected in the secretory cells of HGPIN lesions (open
arrows, Fig. 1Ac). Stromal cells were negative for
KLK4 staining (open arrowheads, Fig. 1Ab,d), as were
cells from sections preabsorbed with KLK4 peptides
prior to immunostaining (Fig. 1Ag), or those treated
only with secondary antibody (data not shown). Com-
parison of KLK4 immunostaining intensity for tissue
sections with different histological types is presented in
Table S2 and summarized in Fig. 1B. The abundance
of KLK4 in BPH, PIN, Gleason 3, 4 and 5 cancers was
significantly higher than in the normal prostate
(P < 0.05). KLK4 staining in PIN, Gleason 3 and 4
cancers, was higher than in BPH (P < 0.001, one-way
ANOVA; Table S3), whereas KLK4 expression in
normal prostate was lower than in BPH (P < 0.023).
However, there was no significant difference between
KLK4 staining intensity in BPH as compared to Glea-
son 5 cancer (P = 0.117), or in PIN versus Grade
3 (P = 0.909), Grade 4 (P = 0.667) or Grade 5
(P = 0.159) PCas (one-way ANOVA; Table S3).
KLK4 expression was also analysed in atypical foci
(high nuclear/cytoplasmic ratio within cells), suspicious
of prostate malignancy, from needle biopsy samples
(Fig. 1Ca–g). Interestingly, atypical foci of cells occa-
sionally interspersed within tumour-adjacent normal
glands also showed strong KLK4 immunostaining
(closed arrows, Fig. 1Cb,d,f,g), in comparison with the
weak or negligible staining in surrounding normal cells.
In the 16 adjacent normal prostate regions analysed, six
foci of cells displayed strong KLK4 staining within atyp-
ical foci; representative sections are shown in Fig. 1Ca–
g. Double immunostaining of KLK4 (brown) and high
molecular weight cytokeratins, specific for basal cells
(red), revealed an absence of the basal cell layer in some
instances where strong KLK4 production was observed
in luminal atypical foci (closed arrows, Fig. 1Cf–g).
3.2. KLK4 specifically activates PAR1 in prostate
stromal cells
PAR1 and PAR2 are KLK4 substrates, expressed in
both malignant and nonmalignant prostate cells, and
involved in PCa progression (Ramsay et al., 2008a,b;
Wang et al., 2010). In order to determine whether
KLK4 could regulate stromal cells via activation of
PAR1 and/or PAR2, the mRNA expression of these
receptors, and that of KLK4, was determined by
RTqPCR analysis of a panel of prostate-derived cell
lines (Fig. S2). In agreement with the pattern of
KLK4 production observed in prostate biopsy samples
(Fig. 1), KLK4 was not expressed in prostate stromal
cells (WPMY1) and lowly expressed in normal epithe-
lial cells (RWPE1). However, its expression gradually
increased in epithelial cell lines derived from hyper-
plastic lesions (RWPE2 and BPH1) and in castrate-
sensitive PCa cell lines (LNCaP and 22RV1). In con-
trast, PAR1 and PAR2 were expressed in epithelial
and stromal cells, with the highest relative level of
PAR1 in WPMY1 cells.
To verify that PAR1 and PAR2 produced by
WPMY1 cells were functional, their ability to mobilize
intracellular calcium was analysed using agonist pep-
tides specific to PAR1 (AP1) and PAR2 (AP2), recom-
binant active human KLK4 or a recombinant mutant
KLK4 form engineered to be catalytically inactive
(mutant KLK4/mKLK4). Both AP1 and AP2 induced
an intracellular calcium flux in WPMY1 cells, demon-
strating that both PAR1 and PAR2 are functional in
this prostate stromal cell line (Fig. 2A). The active
form of KLK4, but not mKLK4, also induced a cal-
cium flux in WPMY1 cells (Fig. 2A). This shows that
KLK4 activates PAR signalling and that this effect is
dependent on its proteolytic activity. To identify the
PAR(s) activated by KLK4 on the surface of prostate
stromal cells, the same calcium flux assays were used
in a desensitization experiment (Holzhausen et al.,
2006; Kawabata et al., 1999). Desensitization of PAR1
suppressed calcium mobilization induced by AP1 or
KLK4, but did not affect that induced by AP2
(Fig. 2B). Conversely, AP1 and KLK4 were still able
to induce calcium mobilization after PAR2 desensitiza-
tion, whereas AP2 was not effective (Fig. 2B). This
demonstrates that calcium mobilization induced by
KLK4 is dependent on PAR1, but not PAR2, activa-
tion. To validate this finding, WPMY1 cells were
transfected with PAR1-targeting or control-siRNA. In
WPMY1 control-siRNA cells, AP1, AP2 and KLK4
induced a calcium flux (Fig. 2C). However, in
WPMY1 PAR1-targeting siRNA cells, only AP2 was
able to induce calcium mobilization (Fig. 2C). This
confirms that KLK4-mediated calcium flux in
WPMY1 cells is dependent on PAR1 activation,
demonstrating that KLK4 can regulate prostate stro-
mal cells through interaction with this receptor. The
same conclusion was made from calcium flux assays
realized in the presence of a potent selective nonpep-
tide PAR1 receptor antagonist (SHC79797) (Fig. S1).
3.3. KLK4 modulates the expression of FGF1,
TAGLN and LOX through activation of PAR1
We have previously identified several genes regulated
by KLK4 in WPMY1 cells (R. A. Fuhrman-Luck &
J. A. Clements, unpublished data) and sought to
determine whether the deregulation of these genes
was mediated by PAR1. The expression of fibroblast
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growth factor-1 (FGF1), FGF5, transgelin (TAGLN)
and lysyl oxidase (LOX) was significantly up-regu-
lated by KLK4 or AP1, but not by mKLK4 or AP2
treatment over 18 h (Fig. 3A). Of note, maximum
KLK4-mediated up-regulation of FGF1 and FGF5
occurred at an earlier time point (6 h) than did up-
regulation of TAGLN and LOX (18 h; Fig. 3A).
To determine the involvement of PAR1 in KLK4-
mediated regulation of the above genes, we analysed
the expression of these genes in WPMY1 cells trans-
fected with PAR1-targeting siRNA, in which a signifi-
cant reduction in PAR1 mRNA levels (~ 90%) was
observed (Fig. 3B). KLK4-mediated up-regulation of
FGF1, LOX and TAGLN was lower upon PAR1 sup-
pression, as compared to controls, whereas no signifi-
cant difference in KLK4-mediated regulation of FGF5
was observed (Fig. 3B). This result suggests that, in
WPMY1 cells, KLK4 up-regulates FGF1, LOX and
TAGLN expression through activating PAR1. To con-
firm this observation, we treated WPMY1 cells with
mKLK4, KLK4, AP1 or AP2 in the presence of
SHC79797, a potent selective nonpeptide PAR1 recep-
tor antagonist (Fig. 3C). Increasing doses of
SHC79797 (0.3 and 0.7 lM) significantly decreased
AP1-mediated up-regulation of FGF1, FGF5,
TAGLN and LOX. However, SHC79797 only inhib-
ited KLK4-mediated up-regulation of FGF1, TAGLN
and LOX, but not FGF5. This confirms that KLK4
up-regulates FGF1, TAGLN and LOX expression
through PAR1, thereby suggesting that KLK4 might
also regulate other signalling pathways independently
of PAR1 leading to FGF5 up-regulation.
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Fig. 2. KLK4 can activate PAR1 in prostate-derived stromal cells. (A) Activation of PARs in WPMY1 cells was analysed by calcium flux
assay. Cells were treated with AP1, AP2 (100 lM), KLK4 and mKLK4 (300 nM). Results are expressed as ratio of fluorescence emission
between excitation at 340 and 380 nM (ratio 340/380, y-axis) over time (x-axis). (B) Calcium flux assay as in (A). Fluorescence emission was
monitored for 600 s and two successive stimulations were made: first stimulation at 30 s with AP1 or AP2 to desensitize PAR1 or PAR2
and second stimulation at 480 s with AP1, AP2 or KLK4. (C) Calcium flux as in A using WPMY1 cells control- or PAR1-siRNA (left and right
panel, respectively).
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Fig. 3. KLK4 regulates gene expression through PAR1 in prostate-derived stromal cells. (A) Gene expression was studied by RTqPCR in
WPMY1 cells treated for 6, 12 or 18 h with mKLK4, KLK4 (20 nM), AP1 or AP2 (100 lM). PBS treatment was used as reference for each
time point. Results are presented as mean  SD of three biological replicates. (B) Gene expression was investigated by RTqPCR in WPMY1
cells transfected with PAR1-siRNA or control-siRNA treated with KLK4 or mKLK4 (20 nM) for 18 h. Expression in WPMY1 cells control-
siRNA treated with mKLK4 was used as reference. Results are presented as mean of relative mRNA expression  SD of three biological
replicates. (C) Gene expression was determined by RTqPCR in WPMY1 cells treated for 6 h with mKLK4, KLK4 (20 nM), AP1 or AP2
(100 lM) in the presence of 0.3 and 0.7 lM of PAR1 inhibitor (SHC79797) or vehicle control (DMSO). Gene expression after mKLK4
treatment was used as reference for each concentration of inhibitor. Results are presented as mean  SD of three biological replicates.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to reference.
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3.4. KLK4-mediated activation of PAR1 increases
the protein abundance of FGF1 and TAGLN
The effect of KLK4 on FGF1 and TAGLN produc-
tion was also analysed at the protein level in cell
lysates of WPMY1 cells treated with mKLK4, KLK4
or AP1 over 6, 12 and 24 h. Results showed that both
KLK4 and AP1 treatment led to an increase in FGF1
protein levels, compared to treatment with mKLK4
(~ 1.6-fold at 6 h, ~ twofold at 12 h and ~ threefold at
24 h; Fig. 4A). FGF1 was not detectable in WPMY1
CM (data not shown). FGF1 protein levels in
WPMY1 cells transfected with PAR1-targeting siRNA
(or control-siRNA) after 24-h treatment with either
mKLK4 or KLK4 showed that the KLK4-mediated
increase in FGF1 abundance was completely inhibited
in PAR1-knockdown cells (Fig. 4B).
Analysis of TAGLN protein was first performed by
immunofluorescence staining in WPMY1 cells treated
with mKLK4, KLK4 or AP1 for 24 h (Fig. 4C). After
KLK4 and AP1 treatment, strong specific intracellular
staining for TAGLN was observed, showing typical
fibrillar organization of this protein (Thompson et al.,
2012), consistent with its association with the
cytoskeleton. Conversely, only weak TAGLN staining
was observed in mKLK4-treated cells. To quantify the
differences in TAGLN protein expression, as well as
to confirm involvement of PAR1, we used western blot
analyses to compare TAGLN abundance in cell lysates
from WPMY1 cells transfected with PAR1-targeting
(or control) siRNA, after treatment with either
mKLK4 or KLK4 for 24 and 48 h. KLK4 treatment
significantly increased the amount of TAGLN in con-
trol cells, compared to treatment with mKLK4 (1.55-
fold and 1.94-fold after 24 and 48 h, respectively;
Fig. 4D). However, this effect was completely inhibited
upon PAR1 knockdown (Fig. 4D), altogether confirm-
ing that KLK4 up-regulates FGF1 and TAGLN at the
protein level, through PAR1 activation.
3.5. FGF1 is involved in the regulation of TAGLN
expression
FGF1, LOX and TAGLN are downstream effectors of
KLK4-mediated PAR1 activation. Interestingly,
KLK4-mediated up-regulation of FGF1 occurs before
up-regulation of LOX and TAGLN (Fig. 3A), suggest-
ing that FGF1 may mediate regulation of the latter
two proteins. To test this hypothesis, we knocked
down FGF1 expression in WPMY1 cells with an
FGF1-targeting siRNA which decreased FGF1 mRNA
and protein levels by ~ 90%, as compared to transfec-
tion with control-siRNA (Fig. 4E,F). In these cells,
KLK4 was still able to increase FGF1 expression, but
to a level significantly lower than in control cells
(Fig. 4E,F). Interestingly, knockdown of FGF1 also
significantly decreased TAGLN expression as well as
its KLK4-mediated up-regulation (Fig. 4E,G), whereas
the basal expression of FGF5 and LOX genes, as well
as their dysregulation by KLK4, was not significantly
different than in WPMY1 control-siRNA cells
(Fig. 4E). Specific dysregulation of TAGLN basal
expression and KLK4-mediated up-regulation of
TAGLN after FGF1 knockdown suggest that FGF1 is
involved in the regulation of TAGLN expression.
3.6. FGF1 and TAGLN are up-regulated by KLK4
in patient-derived stromal cells and
overexpressed in CAFs compared to NPFs
To verify that KLK4-mediated gene regulation was
not only limited to WPMY1 cells, we analysed the
effect of KLK4 on gene expression in patient-derived
primary cultures of nonmalignant fibroblasts (NPFs)
from two patients with PCa (NPF1 and NPF2,
Fig. 5A–C). Using the same protocol as for WPMY1
cells, we showed that 24-h treatment with KLK4
induced a 3.5- to 5.0-fold up-regulation of FGF1 and
a 2.4- to 3.0-fold up-regulation of TAGLN mRNA
expression in NPFs compared to FGF1 and TAGLN
expression in NPFs treated with mKLK4 (Fig. 5A).
These effects were also observed at the protein level
(Fig. 5B,C). KLK4 also significantly increased expres-
sion of LOX, but only in NPF2 (Fig. 5A).
To determine whether these genes up-regulated after
KLK4 treatment were associated with a CAF pheno-
type, we investigated mRNA basal expression of
FGF1, LOX and TAGLN in matched pairs of NPFs
and CAFs from five patients with PCa (Fig. 5D). The
results showed heterogeneity between each NPF/CAF
pair analysed. LOX mRNA expression was signifi-
cantly higher in CAF compared to NPF only in one
NPF/CAF pair of five tested. FGF1 was significantly
up-regulated in CAFs in two of three NPF/CAF pairs,
while TAGLN was significantly up-regulated in CAFs
in all NPF/CAF pairs tested. Of note, the highest up-
regulation of TAGLN and FGF1 was found in the
same NPF/CAF pair (#5).
3.7. KLK4 and PAR1 increase expression of CAF
markers and cell proliferation in a prostate
stromal cell line
To determine whether KLK4 induces a CAF-like phe-
notype in prostate stromal cells, we investigated the
impact of KLK4 treatment on different CAF-related
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features. Compared to NPFs, PCa-derived CAFs have
a higher proliferative rate and a higher expression of
different genes which are recognized as markers of
CAF phenotype such as aSMA, estrogen receptor-a
(ESR1) and secreted frizzled-related protein 1 (SFRP1)
(Clark et al., 2013; Ellem et al., 2014; Joesting et al.,
2005; Ting et al., 2015).
Treatment with KLK4 significantly increased
mRNA expression of aSMA (1.8-fold), ESR1 (1.8-
fold) and SFRP1 (1.9-fold) in WPMY1 cells, com-
pared to cells treated with mKLK4 (or PBS, data not
show) (Fig. 6A). Interestingly, AP1 treatment also sig-
nificantly up-regulated expression of aSMA (1.6-fold),
suggesting an involvement of this receptor in KLK4-
mediated effect on aSMA expression. Effect of KLK4
and AP1 on aSMA production in WPMY1 cells was
confirmed by western blot analysis (1.5-fold and 1.6-
fold increase, respectively) and immunofluorescence
(Fig. 6B, left panel). Similarly, TAGLN production
was stimulated by KLK4 and AP1 treatment (1.8-fold
and 1.5-fold increase, respectively). Expression of
VIM, used as loading control, was unchanged. The
increase in aSMA abundance after AP1 or KLK4
treatment was also confirmed by immunofluorescence,
although only a subpopulation of WPMY1 cells
showed high aSMA expression (Fig. 6B, right panel
and Fig. S2B).
Secondly, we assessed the effect of KLK4 and AP1
on proliferation of WPMY1 cells. For this purpose,
cell density was measured by direct cell counting after
1, 2, 4 and 6 days of treatment with either mKLK4,
KLK4 or AP1 (Fig. 6C). Treatment with AP1 signifi-
cantly increased the proliferation of WPMY1 cells,
compared to cells treated with mKLK4, after 2 days
of treatment and this persisted after 4 and 6 days.
KLK4 also stimulated the proliferation of WPMY1
cells, with a significant pro-proliferative effect observed
after 4 and 6 days.
3.8. KLK4 modulates the secretome of WPMY1
prostate stromal cells increasing the secretion of
several proangiogenic factors
CAFs regulate tumorigenesis by secreting protumori-
genic factors. To determine whether KLK4 modulated
the secretome of stromal cells, we analysed the
WPMY1 cell secretome, following KLK4 or mKLK4
treatment, using a cytokine array permitting simultane-
ous analysis of 102 soluble secreted factors. These
results identified eight secreted proteins with a relative
signal intensity greater than 10% of the mean intensity
of control spots, and with a fold difference of
2 ≤ 0 ≥ 2 between KLK4- and mKLK4-treated sam-
ples (Fig. 6D). Three cytokines were decreased in CM
from cells treated with KLK4, compared to treatment
with mKLK4: IGF-binding protein 3 (IGFBP3; 10-
fold decrease), monocyte chemoattractant protein-1
(MCP-1; twofold decrease) and platelet-derived growth
factor-AA (PDGF-AA; 3.8-fold decrease). Conversely,
the five other cytokines were increased in CM from
WPMY1 cells treated with KLK4, as compared to
mKLK4. These were Dkk-1 (Dickkopf-related protein
1; 2.2-fold), GDF15 (growth differentiation factor 15;
12.1-fold), HGF/SF (2.2-fold), IL8 (4.2-fold) and vas-
cular endothelial growth factor (VEGF; 2.2-fold).
Results for other cytokines analysed by the array are
presented in Table S4.
To confirm the results obtained with the cytokine
array, we determined the levels of IL8 and VEGF in
CM from WPMY1 cells using specific ELISAs. In
agreement with the cytokine array results, the levels of
IL8 were higher in the KLK4-treated WPMY1 cell
secretome, compared to cells treated with mKLK4
(52.8 vs 32.3 pgmL1; Fig. 6E, left panel). Moreover,
although an increase in IL8 was still observed in CM
of control cells after KLK4 treatment (49.5 vs
19.2 pgmL1), PAR1 suppression significantly reduced
Fig. 4. KLK4 regulates protein expression through PAR1 in prostate-derived stromal cells. (A–B) FGF1 protein in 30 lg of total cellular
proteins was determined using FGF1-ELISA in (A) WPMY1 cells treated for 6, 12 or 18 h with mKLK4, KLK4 (20 nM) or AP1 (100 lM), or (B)
WPMY1 cells transfected with PAR1-siRNA or control-siRNA and treated with KLK4 or mKLK4 (20 nM) for 24 h. Results are expressed as
mean  SD from three biological replicates. (C) TAGLN expression was determined by immunofluorescent detection in WPMY1 cells
treated for 48 h with mKLK4, KLK4 (20 nM) or AP1 (100 lM). Nuclei were stained using DAPI. Representative images are shown, scale bar:
20 lm. (D) TAGLN expression was determined by western blot in WPMY1 cells transfected with PAR1-siRNA or control-siRNA and treated
for 24 and 48 h with mKLK4 or KLK4 (20 nM). Densitometry analysis was performed using IMAGEJ software on three independent
experiments. (E–G) WPMY1 cells transfected with FGF1-siRNA or control-siRNA were treated for 24 h with mKLK4 or KLK4 (20 nM). (E).
Gene expression was obtained by RTqPCR with expression observed for WPMY1 cells control-siRNA treated with mKLK4 as reference.
Results are presented as mean  SD of three biological replicates. (F) The amount of FGF1 protein in 30 lg of total cellular proteins was
determined using FGF1-ELISA. Results are expressed as mean  SD calculated on three biological replicates. (G) TAGLN protein expression
was determined by western blot as in D. Densitometry analysis was performed using IMAGEJ software on three independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001 compared to reference.
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the KLK4-mediated increase in IL8 (28.4 vs
23.9 pgmL1), demonstrating that PAR1 plays a
major role in KLK4-mediated release of IL8 by
WPMY1 cells (Fig. 6E, left panel). The same conclu-
sion can be made for KLK4-mediated VEGF release,
as KLK4 treatment of wild-type and control WPMY1
cells led to an increase in the levels of secreted VEGF
(236.5 vs 127.8 pgmL1 and 214.0 vs 112.5 pgmL1,
respectively), whereas no significant change was
observed in WPMY1 cells transfected with PAR1-tar-
geting siRNA (78.2 vs 89.2 pgmL1; Fig. 6E, right
panel). The effect of KLK4 on IL8 and VEGFA
expression was also confirmed at mRNA level by
RTqPCR in WPMY1 cells as well as in NPFs/CAFs
(Fig. S2C,D).
Interestingly, analysis of mRNA expression levels of
these two factors in matched pairs of NPFs and CAFs
from five patients with PCa showed that IL8 mRNA
expression was very heterogeneous: one patient pre-
sented a significantly higher level of IL8 in CAF com-
pared to NPF, whereas two patients presented a
significantly lower level in CAF. However, VEGFA
mRNA expression level was significantly higher in
three NPF/CAF pairs of five tested (Fig. S2E).
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3.9. KLK4-treated WPMY1 cells have an increased
proangiogenic potential, partially mediated by
VEGF
To determine the functional consequences of KLK4-
induced modifications of the WPMY1 secretome in the
TME, we analysed the proangiogenic activity of
WPMY1 CM via its impact on proliferation of
HUVEC endothelial cells. Firstly, live monitoring of
endothelial cell growth showed increased proliferation
of HUVEC cells treated for 24 and 48 h with CM
from KLK4- and AP1-treated WPMY1 cells, com-
pared to cells treated with CM from mKLK4-treated
WPMY1 cells (~ 1.5-fold at 24 h and ~ twofold at
48 h; Fig. 6F, left panel). Secondly, we analysed
HUVEC proliferation after 48-h treatment with CM
from KLK4- or AP1-treated WPMY1 cells, supple-
mented with a VEGF-neutralizing antibody or an iso-
type control (rabbit IgG). Our results confirmed that
CM from WPMY1 cells treated with AP1 or KLK4
stimulated proliferation of HUVEC cells, compared to
CM from WPMY1 cells treated with mKLK4. In
addition, the VEGF-neutralizing antibody reduced the
proliferation of HUVEC cells that was induced by
KLK4- or AP1-treated WPMY1 CM, or by normal
EGM, as compared to that observed in the presence of
the IgG isotype control (Fig. 6F, right panel). This
demonstrates that VEGF mediates these proangiogenic
effects.
4. Discussion
In this report, we demonstrated that KLK4 can induce
a CAF-like phenotype, which is essential for cancer
progression, in normal prostate stromal cells, and may
be a key contributor to CAF differentiation in PCa.
We have shown in normal prostate WPMY1 stromal
cells that KLK4 activates PAR1 inducing CAF-related
features such as the modulation of the expression of
several factors involved in the establishment of the
CAF phenotype, the stimulation of stromal cell growth
and the modulation of the stromal cell secretome in
favour of a proangiogenic response. These gene expres-
sion changes were reproduced in NPFs and matched
CAFs from patients with PCa, supporting the biologi-
cal relevance of our findings. Of note, KLK4 protein
is overexpressed in hyperplastic prostate epithelial
cells, PIN lesions and malignant epithelium where it
could be proteolytically activated by another protease
expressed in prostate tissues such as KLK3, KLK11 or
a member of MMP family (Bi et al., 2010; Yoon et al.,
2007) and interact with adjacent stromal cells, suggest-
ing that KLK4 secretion from these cells could be a
key player in the early stromal differentiation to the
CAF phenotype.
Herein, we have confirmed the overexpression of
KLK4 in PCa tissues compared to normal prostate as
previously demonstrated by several independent stud-
ies (Mukai et al., 2015; Seiz et al., 2010; Veveris-Lowe
et al., 2005). In addition, by extending our analysis to
nonmalignant prostate lesions, our study is the first to
reveal a significant KLK4 overexpression in nonmalig-
nant prostate lesions (BPH, PIN and HGPIN) com-
pared to normal prostate gland. Intriguingly, our
analysis also revealed that KLK4 is overexpressed in
foci of atypical epithelial cells in normal prostate
glands particularly where basal cells are absent. Over-
production of KLK4 by nonmalignant prostate
lesions, which are often considered as precursors of
PCa, or at least are associated with the presence of
PCa (Chrisofos et al., 2007; Eminaga et al., 2013), and
at the interface of epithelial cells and stroma, high-
lights a possible involvement of KLK4 in mediating
interactions between epithelium and stromal cells in
the early stages of PCa development.
KLK4 exerts its biological effects through multiple
molecular mechanisms, such as regulation of ECM
remodelling (Fuhrman-Luck et al., 2016; Zhu et al.,
2014), control of activity of growth factor- and hor-
mone-related signalling pathways (Mukai et al., 2008,
2015; Sanchez et al., 2012), modulation of the prote-
olytic network (Dong et al., 2013; Yoon et al., 2007)
and cleavage of several membrane-bound proteins
(Lisle et al., 2015; Matsumura et al., 2005; Ramsay
et al., 2008a,b), notably activation of PARs. Using
two different approaches to inhibit PAR1 activation
(desensitization and siRNA-mediated silencing), we
identified PAR1 to be predominantly activated by
KLK4 in WPMY1 cells. This observation was in total
agreement with the higher expression of PAR1 than
that of PAR2 in these cells as well as by the higher
efficiency of KLK4 to activate PAR1 than PAR2
(Gratio et al., 2010; Ramsay et al., 2008a). As KLK4
is overproduced by premalignant prostate epithelial
cells as well as PCa cells and PAR1 is deregulated in
the reactive stroma associated with BPH and PCa
(Ramsay et al., 2008b; Wang et al., 2010; Zhang et al.,
2009), we hypothesize that KLK4–PAR1 interactions
play an important role in prostate stromal cell
activation.
KLK4 affects downstream gene expression in
WPMY1 cells, regulating expression of several genes
(FGF1, FGF5, LOX and TAGLN). Using PAR1
chemical inhibition and siRNA-mediated PAR1 silenc-
ing, we confirmed that KLK4-mediated up-regulation
of FGF1, LOX and TAGLN was dependent on
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PAR1, whereas FGF5 was regulated independently of
this receptor. Additionally, FGF5 gene was regulated
by both the PAR1 agonist and KLK4 although the
impact of KLK4 on its expression is PAR1 indepen-
dent. This leads to the hypothesis that KLK4-mediated
PAR1 activation induces different downstream sig-
nalling compared to PAR1-agonist peptides. Addi-
tional experiments must be performed to clearly
determine which downstream signalling pathway
induced by KLK4-mediated PAR1 activation is
responsible for regulation of FGF1, TAGLN and
LOX expression in prostate stromal cells as well as to
evaluate the differences between PAR1 activation
mediated by activating peptides and KLK4.
Recently, several studies demonstrated that contrary
to other members of the FGF family, FGF1 lacks a
secretion signal peptide and could exert its effects in
an intracrine manner (Bober et al., 2016; Delmas
et al., 2016). As KLK4-mediated up-regulation of
FGF1 at the mRNA level occurred at an earlier time
point compared to LOX and TAGLN up-regulation,
we investigated the involvement of FGF1 in the regu-
lation of LOX and TAGLN expression. Using a
FGF1-siRNA, we showed that this growth factor was
necessary for TAGLN expression as well as for
KLK4-mediated TAGLN up-regulation at both the
mRNA and protein levels. In contrast, silencing of
FGF1 did not modulate FGF5 and LOX expression
as well as the effect of KLK4 on their expression. It
would be of interest to further confirm this observed
relationship between FGF1 and TAGLN expression
and to determine the associated mechanisms.
We have also confirmed that the KLK4 impact on
gene expression in prostate stromal cells is not
restricted to WPMY1 cells. KLK4 treatment of pri-
mary NPF and matched CAF led to up-regulation of
FGF1 and TAGLN gene and protein levels in both
NPFs and CAFs from two patients with PCa. How-
ever, KLK4-mediated up-regulation of IL8 and
VEGFA has been confirmed in only one of the two
patients tested, demonstrating that heterogeneity of
stromal cells will likely modulate the effects of KLK4.
Recently, both FGF1 and TAGLN have been identi-
fied as highly correlated cancer biomarkers in a cross-
tissue analysis of gene expression in cancer tissues
(Kosti et al., 2016). We also confirmed that KLK4-
mediated gene regulation is associated with the appear-
ance of the CAF phenotype in prostate fibroblasts, as
genes up-regulated by KLK4 in prostate fibroblasts
were also deregulated in prostate-derived CAFs com-
pared to matching NPFs. Despite the heterogeneity of
CAFs, significant TAGLN up-regulation was observed
in five of five CAFs tested compared to NPF. This up-
regulation of TAGLN in CAFs is in agreement with
studies demonstrating up-regulation of this protein in
the majority of PCa-derived CAFs (Webber et al.,
2016) and in gastric carcinoma-derived CAFs where it
regulates CAF-mediated metastasis of cancer cells
through the regulation of MMP2 expression (Yu et al.,
2013). TAGLN is an actin-binding protein involved in
the regulation of cell contractibility, which is
recognized as an early marker of smooth muscle cells
differentiation. However, its role in PCa cells and
prostate-derived stromal cells and CAFs has not been
Fig. 6. KLK4 induces CAF-related features in prostate stromal cells through PAR1. (A) Gene expression of aSMA, ESR1 and SFRP1 was
determined by RTqPCR in WPMY1 cells treated with mKLK4, KLK4 or AP1 for 24 h. Results are expressed as mean  SD calculated on
three biological replicates, *P < 0.05, **P < 0.01, ***P < 0.001. (B–C) WPMY1 cells were treated every 48 h with mKLK4, KLK4 (20 nM) or
AP1 (100 lM) for 6 days. (B) aSMA and TAGLN expression was determined by western blot (left panel). Densitometry analysis was
performed using imageJ on three independent experiments. aSMA expression was also determined by immunofluorescent staining (right
panel) and the fluorescence quantified (Fig. S2B). (C). Proliferation was measured by direct cell counting using InCell analyzer and
CELLPROFILER software based on nuclei staining (DAPI). Results are presented as mean  SD of three biological replicates, *P < 0.05,
**P < 0.01, ***P < 0.001. (D) Conditioned media (CM) of WPMY1 cells treated for 48 h with KLK4 and mKLK4 (20 nM) were analysed using
a protein array (Human XL Cytokine array). For each factor analysed, results are expressed as mean  SD of relative intensity of duplicate
spots compared to mean intensity of six positive control spots present on each array (%). Full analysis of the cytokine array can be found in
Table S4. (E) IL8 and VEGF concentrations were determined by ELISA in conditioned media (CM) from wild-type WPMY1 cells or WPMY1
cells transfected with PAR1-siRNA or control-siRNA treated for 24 h with mKLK4 or KLK4 (20 nM). Results are expressed as mean  SD
calculated on three biological replicates. Statistical analysis was performed using t-test, Mann–Whitney with *P < 0.05, **P < 0.01,
***P < 0.001 compared to reference. (F) Effect of CM prepared in E on proliferation of HUVEC cells was analysed. Left panel: HUVEC
growth in the presence of WPMY1-derived CM was followed by live cell imaging (Incucyte) for 48 h. Relative confluence was calculated
using confluence at 24 h of HUVEC cells treated with mKLK4-treated WPMY1’s CM as reference. Right panel: HUVEC growth in the
presence of WPMY1-derived CM or endothelial cells growth medium (EGM) was analysed by DNA assay after 48 h of treatment in the
presence of an IgG isotype control or a VEGF-neutralizing IgG. Relative fluorescence intensity was calculated using mKLK4-treated
WPMY1’s CM containing IgG isotype control as reference. Results are presented as mean  SD of three biological replicates, *P < 0.05,
**P < 0.01, ***P < 0.001 compared to reference.
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extensively studied (Dvorakova et al., 2014). Further
studies are required to clearly identify the biological
role of TAGLN in the prostate tumour stromal
microenvironment, particularly in the promotion of
CAF differentiation. Overall, the results obtained with
primary NPFs and CAFs confirm that KLK4 can reg-
ulate gene expression in prostate-derived stromal cells
notably inducing expression of genes associated with
the CAF-like phenotype.
Investigation of the effect of KLK4 on the prostate
stromal cell secretome showed that KLK4 modulates
several soluble factors playing important roles in PCa
progression. Several secreted factors (IGFBP3, MCP-1
and PDGF-AA) showed decreased expression profiles
in the secretome of cells treated with KLK4. Interest-
ingly, IGFBP-3, a protein chaperone of IGFs, and
PDGF-AA, a growth factor involved in the regulation
of mesenchymal cell proliferation and tumour progres-
sion, are two putative substrates of KLKs in a model
of ovarian cancer cells overexpressing KLK4-7
(Matsumura et al., 2005; Prassas et al., 2015; Shahi-
nian et al., 2014), which may explain their decrease in
expression after KLK4 treatment. Conversely, Dkk-1,
GDF15, HGF/SF, IL8 and VEGF levels were
increased in the secretome of cells treated with KLK4.
HGF/SF, the ligand of HGF receptor MET, is
involved in PCa progression stimulating proliferation
and migration of cancer cells as well as prostate
fibroblasts and CAFs (Han et al., 2016; Varkaris
et al., 2011). Previous studies have demonstrated that
KLK4 regulates the activation of the HGF pathway in
PCa (Mukai et al., 2008, 2015). The increase in HGF/
SF release as well as of expression of the HGF recep-
tor MET in WPMY1 cells after KLK4 treatment (data
not shown) could explain the increased proliferation of
WPMY1 cells after treatment with this protease. IL8
and VEGF are two secreted factors considered as a
protumorigenic factor notably because of their role
in the regulation of angiogenesis (Culig 2013,
Karagiannis et al., 2014). Of note, IL8 has been
already identified as a regulator of interactions
between prostate stromal and epithelial cells in the
context of PCa (Kogan-Sakin et al., 2009) and VEGF
has been found to be produced at higher levels by
CAFs compared to normal fibroblasts (Augsten, 2014;
Ishii et al., 2011). In our study, we have also shown
that both IL8 and VEGF modulations by KLK4 were
mediated through a PAR1-dependent mechanism as
Prostate Fibroblasts
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?
CAF-like features
Other 
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Fig. 7. Schematic for the possible involvement of KLK4 in early stages of prostate cancer. KLK4 is produced by premalignant cells in benign
prostatic hyperplasia and PIN lesions and acts on prostate fibroblast stromal cells through activation of PAR1 as well as other undetermined
pathways conducting to gene regulation of IL8, FGF1, LOX, aSMA, TAGLN and VEGFA (PAR1 dependent) and FGF5, ESR1 and SFRP1
(PAR1 independent). In response to KLK4 stimulation, prostate fibroblast stromal cells present a higher proliferation rate and a modification
of their secretome (increase in Dkk-1, GDF15, HGF/SF and decrease in IGFBP3, MCP1 and PDGF-AA) in favour of a proangiogenic response
(increase in IL8 and VEGF), which could ultimately lead to the development of a proangiogenic microenvironment necessary for prostate
cancer progression. We could also hypothesize that modification of prostate fibroblast secretome after KLK4 stimulation could directly
influence proliferation/migration/survival of prostate cancer cells.
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previously demonstrated in another fibroblast cell line
after treatment with thrombin, the classical activator
of PAR1 (Wang et al., 2010). Finally, we have also
observed that KLK4 or AP1 modulated proangiogenic
effect of stromal cell-conditioned media is dependent,
at least partially, on VEGF release. This result rein-
forces our hypothesis of an induction of a CAF phe-
notype by KLK4 as CAFs are known to have a high
proangiogenic capacity through production and release
of proangiogenic molecules (Erez et al., 2010; Madar
et al., 2013; Shiga et al., 2015).
Overall, our study provides the first evidence for the
involvement of KLK4 secreted by premalignant and
malignant prostate cells in the induction of CAF-
related features in prostate-derived stromal cells
(Fig. 7). We show that this effect is partially mediated
through the activation of the PAR1 receptor expressed
in stromal cells adding a new role for this receptor
during cancer progression, in addition to its involve-
ment in cancer cell invasion and in the regulation of
angiogenesis following its activation by thrombin (Yin
et al., 2003a,b). Moreover, this study suggests that
TAGLN expression could be used as a marker of the
CAF phenotype in the context of PCa as its expression
is elevated in CAFs compared to NPFs. Future studies
will be conducted to define other possible pathways
(HGF, TGF-b) regulated by KLK4 in prostate fibrob-
lasts, to analyse its effect in the presence of other
factors regulating the establishment of the CAF phe-
notype, as well as to confirm its involvement in induc-
tion of the CAF phenotype in vivo. Finally, evaluation
of KLK4 and TAGLN expression in prostate biopsies
could determine whether the expression of these two
factors in premalignant prostate lesions could predict
the development of PCa.
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Supporting information
Additional Supporting Information may be found
online in the supporting information tab for this
article:
Fig. S1. Activation of PARs in WPMY1 cells was
analysed by calcium flux assay in presence of 0.3 and
0.7 lM of PAR1 inhibitor (SHC79797) or vehicle con-
trol (DMSO).
Fig. S2. (A) The expression of KLK4, PAR1 and
PAR2 genes have been determined by RTqPCR in dif-
ferent cancerous and noncancerous prostate-derived
cell lines (RWPE1, RWPE2, BPH, LNCaP, 22RV1,
PC3, DU145 and WPMY1). Gene expression from
PC3 cells were used as reference. Statistical analysis
was performed to compare gene expression between
WPMY1 and other cell lines tested using One-way
ANOVA test. PAR1 and PAR2 expression levels have
been compared in each cell line tested. (B) aSMA pro-
tein expression was determined by immunofluorescent
staining (Fig. 6B) and the fluorescence quantified using
Incucyte analyser. Results are expressed as mean  SD
of relative fluorescent intensity of each field analysed
from 3 biological replicates. (C) Gene expression was
investigated by RTqPCR in WPMY1 cells transfected
with PAR1-siRNA or control-siRNA before and after
treatment with KLK4 or mKLK4 (20 nM) for 18 h.
Expression in WPMY1 cells control-siRNA treated
with mKLK4 was used as reference. Results are pre-
sented as mean  SD of 3 biological replicates. (D)
Matched NPF/CAFs isolated from 2 different patients
were treated for 24 h with KLK4 and mKLK4
(20 nM). Gene expression was obtained by RTqPCR.
Gene expression observed for NPF cells treated with
mKLK4 were used as reference for each patient.
Results are presented as mean  SD of 2 biological
replicates. Statistical analysis was performed using
One-way ANOVA test Kruskal and Wallis,
**P < 0.01, ***P < 0.001 compared to reference. (E)
Gene expression was analysed in matched NPF/CAF
isolated from 5 different patients in normal culture
condition for 48 h. Gene expression observed for NPF
cells were used as reference for each patient. Results
are presented as mean  SD of 3 technical replicates.
Statistical analysis was performed using One-way
ANOVA test Bonferroni’s multiple comparison,
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*P < 0.05, **P < 0.01, ***P < 0.001 compared to
reference.
Table S1. RTqPCR primers used.
Table S2. Summary of KLK4 expression in different
prostate histopathologies. Staining intensity was scored
from 0 to 3 (0 for no staining, 1 for weak staining, 2
for moderate, and 3 for strong staining). 1Includes
only one normal prostate tissue and 15 adjacent nor-
mal prostate regions.
Table S3. Comparison of KLK4 expression by one-
way ANOVA analysis. 1P values are shown for pair-
wise comparison.
Table S4. Summary of relative intensity for each fac-
tor, as analysed by cytokine array. For each factor,
average intensity was calculated based on two spots
present on the array and was divided by the average
intensity of positive control spots. The fold change
between the secretomes of WPMY1 cells treated with
mKLK4 or KLK4 was calculated by dividing cor-
rected mean intensity calculated for each factor.
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